Valuation
- Market cap
- 114,973,000
- Revenue TTM
- $0
- Net income TTM
- $-24,340,000
- P/E (trailing)
- 0.00
- P/E (forward)
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 2,089,900
- Avg volume
- 771,430
- Day's range
- $2.19 – $2.49
- Shares out
- 48,308,000
- Stochastic %K
- 79%
- Beta
- -0.85
- Analysts
- Strong Buy
- Price target
- $8.00
Company profile
Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Cassava Sciences, Inc. and...
Show more
Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Cassava Sciences, Inc. and changed its name to Filana Therapeutics, Inc. in March 2026. The company was incorporated in 1998 and is based in Austin, Texas.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 512 501 2444
- Website
- https://www.cassavasciences.com
- Address
- 6801 N. Capital of Texas Highway, Suite 300 Building 1, Austin, United States
Latest news
No headlines yet.
